phosphonoacetic acid has been researched along with Herpes Genitalis in 15 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
Herpes Genitalis: Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double blind, placebo controlled trial was performed in nine sexually transmitted diseases (STD) clinics in the United Kingdom and the Netherlands to investigate the efficacy of trisodium phosphonoformate (foscarnet) cream in treating recurrent genital herpes simplex virus (HSV) infection." | 9.06 | Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study. ( Barton, SE; Essex-Cater, AJ; Kinghorn, GR; Kuijpers, MH; Munday, PE; Notowicz, A; Rashid, S; Schuller, JL; Stolz, E; van der Meijden, WI, 1986) |
| "Clinic-initiated topical treatment of recurrent genital herpes with foscarnet cream (concentration, 0." | 9.06 | Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial. ( Aoki, FY; Bright, C; Kaluski, J; Lawee, D; Poisson, M; Portnoy, J; Sacks, SL; Schlech, W; Tyrrell, DL, 1987) |
| "The activity of phosphonoacetic acid (PAA) and phosphonoformic acid (PFA) against four strains of herpes simplex virus type 1 (HSV-1) and four strains of HSV-2 were compared in tissue culture and in a murine model of genital herpes." | 7.66 | A comparison of phosphonoacetic acid and phosphonoformic acid activity in genital herpes simplex virus type 1 and type 2 infections of mice. ( Glasgow, LA; Kern, ER; Overall, JC; Richards, JT, 1981) |
| "Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42." | 6.67 | A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. ( Chatis, P; Crumpacker, C; Davis, R; Hafner, R; Kessler, HA; Landry, B; Mills, J; Rush, J; Safrin, S, 1991) |
| "Treatment with foscarnet cream was not associated with any significant side effects." | 6.66 | Foscarnet (phosphonoformate sodium) in the treatment of recurrent male genital herpes. ( Doraisingham, S; Lee, CT; Lim, KB; Ling, AE; Tan, T; Thirumoorthy, T, 1986) |
| "Foscarnet treated men with subpreputial lesions had a shorter period of ulcers (1." | 6.66 | Topical treatment of recurrent genital herpes infections with foscarnet. ( Lernestedt, JO; Lycke, E; Ogenstad, S; Wallin, J, 1985) |
| "A double blind, placebo controlled trial was performed in nine sexually transmitted diseases (STD) clinics in the United Kingdom and the Netherlands to investigate the efficacy of trisodium phosphonoformate (foscarnet) cream in treating recurrent genital herpes simplex virus (HSV) infection." | 5.06 | Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study. ( Barton, SE; Essex-Cater, AJ; Kinghorn, GR; Kuijpers, MH; Munday, PE; Notowicz, A; Rashid, S; Schuller, JL; Stolz, E; van der Meijden, WI, 1986) |
| "Clinic-initiated topical treatment of recurrent genital herpes with foscarnet cream (concentration, 0." | 5.06 | Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial. ( Aoki, FY; Bright, C; Kaluski, J; Lawee, D; Poisson, M; Portnoy, J; Sacks, SL; Schlech, W; Tyrrell, DL, 1987) |
| "In an AIDS patient who had repeated successful treatment with acyclovir in his history, erosive herpes perianalis with herpes proctitis appeared, which persisted over several weeks." | 3.68 | [Chronic erosive, therapy-resistant perianal herpes (type II) with herpes proctitis in AIDS]. ( Bratzke, B; Ehlers, G; Orfanos, CE; Stavermann, T, 1991) |
| "The activity of phosphonoacetic acid (PAA) and phosphonoformic acid (PFA) against four strains of herpes simplex virus type 1 (HSV-1) and four strains of HSV-2 were compared in tissue culture and in a murine model of genital herpes." | 3.66 | A comparison of phosphonoacetic acid and phosphonoformic acid activity in genital herpes simplex virus type 1 and type 2 infections of mice. ( Glasgow, LA; Kern, ER; Overall, JC; Richards, JT, 1981) |
| "Topical treatment of herpes genitalis in female guinea pigs with 2-deoxy-D-glucose in either agarose gels or miconazole nitrate ointments failed to prevent the development of genital lesions or to reduce the mean titers of recoverable virus in vaginal swabs from infected animals." | 3.66 | Lack of efficacy of 2-deoxy-D-glucose in the treatment of experimental herpes genitalis in guinea pigs. ( Arnett, G; Drennen, DJ; Shannon, WM, 1982) |
| "Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42." | 2.67 | A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. ( Chatis, P; Crumpacker, C; Davis, R; Hafner, R; Kessler, HA; Landry, B; Mills, J; Rush, J; Safrin, S, 1991) |
| "Treatment with foscarnet cream was not associated with any significant side effects." | 2.66 | Foscarnet (phosphonoformate sodium) in the treatment of recurrent male genital herpes. ( Doraisingham, S; Lee, CT; Lim, KB; Ling, AE; Tan, T; Thirumoorthy, T, 1986) |
| "Foscarnet treated men with subpreputial lesions had a shorter period of ulcers (1." | 2.66 | Topical treatment of recurrent genital herpes infections with foscarnet. ( Lernestedt, JO; Lycke, E; Ogenstad, S; Wallin, J, 1985) |
| "The mechanism of recurrence is yet not fully elucidated and therapy still remains a problem." | 2.36 | [Herpes simplex]. ( Fanta, D, 1981) |
| " In a comparative study with this 3-day dosage schedule, the efficacy of daily doses of 50 mg of FMAU per kg was greater than that of the same doses of FIAC and FIAU, in that order; all these were more effective than daily doses of 50, 100, or 200 mg of acyclovir or of 500 mg of phosphonoformic acid per kg." | 1.27 | Treatment of primary acute genital herpes in guinea pigs by intraperitoneal administration of fluoropyrimidines. ( Hsiung, GD; Mayo, DR, 1984) |
| "Using a guinea pig model of genital herpes simplex virus (HSV) type 2 infection, phosphonoformate treatment initiated after the onset of symptoms had a therapeutic effect on the outcome of disease." | 1.27 | Effect of phosphonoformate on symptomatic genital herpes simplex virus type 2 infection of guinea pigs. ( Hsiung, GD; Lucia, HL; Mayo, DR, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (73.33) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mayo, DR | 2 |
| Hsiung, GD | 2 |
| Kern, ER | 1 |
| Richards, JT | 1 |
| Overall, JC | 1 |
| Glasgow, LA | 1 |
| Fanta, D | 1 |
| Lucia, HL | 1 |
| Shannon, WM | 1 |
| Arnett, G | 1 |
| Drennen, DJ | 1 |
| Li, YY | 1 |
| Minagawa, H | 1 |
| Tanaka, S | 1 |
| Mori, R | 1 |
| Safrin, S | 1 |
| Crumpacker, C | 1 |
| Chatis, P | 1 |
| Davis, R | 1 |
| Hafner, R | 1 |
| Rush, J | 1 |
| Kessler, HA | 1 |
| Landry, B | 1 |
| Mills, J | 1 |
| Bratzke, B | 1 |
| Orfanos, CE | 1 |
| Stavermann, T | 1 |
| Ehlers, G | 1 |
| Spitzbart, H | 1 |
| Seyffert, C | 1 |
| Thust, U | 1 |
| Chatis, PA | 1 |
| Miller, CH | 1 |
| Schrager, LE | 1 |
| Crumpacker, CS | 1 |
| Youle, MM | 1 |
| Hawkins, DA | 1 |
| Collins, P | 1 |
| Shanson, DC | 1 |
| Evans, R | 1 |
| Oliver, N | 1 |
| Lawrence, A | 1 |
| Barton, SE | 1 |
| Munday, PE | 1 |
| Kinghorn, GR | 1 |
| van der Meijden, WI | 1 |
| Stolz, E | 1 |
| Notowicz, A | 1 |
| Rashid, S | 1 |
| Schuller, JL | 1 |
| Essex-Cater, AJ | 1 |
| Kuijpers, MH | 1 |
| Sacks, SL | 1 |
| Portnoy, J | 1 |
| Lawee, D | 1 |
| Schlech, W | 1 |
| Aoki, FY | 1 |
| Tyrrell, DL | 1 |
| Poisson, M | 1 |
| Bright, C | 1 |
| Kaluski, J | 1 |
| Lim, KB | 1 |
| Doraisingham, S | 1 |
| Thirumoorthy, T | 1 |
| Lee, CT | 1 |
| Ling, AE | 1 |
| Tan, T | 1 |
| Wallin, J | 1 |
| Lernestedt, JO | 1 |
| Ogenstad, S | 1 |
| Lycke, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Infection in Patients With the Acquired Immunodeficiency Syndrome: A Randomized Multicenter Study of Foscarnet Versus Vidarabine[NCT00000985] | Phase 3 | 26 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for phosphonoacetic acid and Herpes Genitalis
| Article | Year |
|---|---|
[Herpes simplex].
Topics: Adolescent; Adult; Amantadine; Antigens, Viral; Cell Transformation, Viral; Female; Foscarnet; Herpe | 1981 |
5 trials available for phosphonoacetic acid and Herpes Genitalis
| Article | Year |
|---|---|
A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; | 1991 |
Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study.
Topics: Administration, Topical; Clinical Trials as Topic; Double-Blind Method; Female; Foscarnet; Herpes Ge | 1986 |
Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial.
Topics: Administration, Topical; Adolescent; Adult; Antiviral Agents; Clinical Trials as Topic; Double-Blind | 1987 |
Foscarnet (phosphonoformate sodium) in the treatment of recurrent male genital herpes.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antiviral Agents; Clinical Trials as Topic; Double | 1986 |
Topical treatment of recurrent genital herpes infections with foscarnet.
Topics: Administration, Topical; Adult; Clinical Trials as Topic; Double-Blind Method; Erythema; Female; Fos | 1985 |
9 other studies available for phosphonoacetic acid and Herpes Genitalis
| Article | Year |
|---|---|
Treatment of primary acute genital herpes in guinea pigs by intraperitoneal administration of fluoropyrimidines.
Topics: Acyclovir; Animals; Antiviral Agents; Arabinofuranosyluracil; Cytarabine; Female; Foscarnet; Guinea | 1984 |
A comparison of phosphonoacetic acid and phosphonoformic acid activity in genital herpes simplex virus type 1 and type 2 infections of mice.
Topics: Animals; Antiviral Agents; Drug Evaluation, Preclinical; Female; Foscarnet; Ganglia, Spinal; Herpes | 1981 |
Effect of phosphonoformate on symptomatic genital herpes simplex virus type 2 infection of guinea pigs.
Topics: Animals; Antiviral Agents; Drug Evaluation, Preclinical; Female; Foscarnet; Ganglia, Spinal; Guinea | 1983 |
Lack of efficacy of 2-deoxy-D-glucose in the treatment of experimental herpes genitalis in guinea pigs.
Topics: Administration, Topical; Animals; Deoxy Sugars; Deoxyglucose; Female; Guinea Pigs; Herpes Genitalis; | 1982 |
Suppression of infectious virus spread to the liver by foscarnet following lethal infection of acyclovir-resistant herpes simplex virus type 2 in mice.
Topics: Acyclovir; Animals; Arabinonucleosides; Brain; Chlorocebus aethiops; Drug Resistance, Microbial; Fos | 1995 |
[Chronic erosive, therapy-resistant perianal herpes (type II) with herpes proctitis in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Dose-Response Relationship, | 1991 |
[Triapten ointment in the treatment of herpes genitalis in the female].
Topics: Antiviral Agents; Female; Foscarnet; Herpes Genitalis; Humans; Ointments; Phosphonoacetic Acid; Uter | 1990 |
Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; | 1989 |
Acyclovir-resistant herpes in AIDS treated with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Drug Resistance, Microbial; Female; Foscarnet; | 1988 |